期刊文献+

肝硬化食管胃静脉曲张出血的奥曲肽治疗观察

Application of Octreotide on Esophageal and Gastric Variceal Bleeding Patients with Cirrhotic Portal Hypertension
暂未订购
导出
摘要 目的观察和分析奥曲肽治疗食管胃静脉曲张出血的疗效和耐受性。方法 90例患者随机分为奥曲肽治疗组(48例)和垂体后叶素+硝酸甘油对照组(42例)。比较两组的总有效率(显效率+有效率)、治愈率,平均止血时间及药物不良反应,两组患者均于出院2周后随访并作统计学处理。结果总有效率:治疗组为93.8%,对照组78.6%(P〈0.05);治愈率:治疗组91.7%,对照组76.2%(P〈0.05);平均止血时间(h):治疗组13.8±6(h),对照组18.7±5(h)(P〈0.05)。药物不良反应:两组未见明显不良反应。结论奥曲肽治疗食管胃静脉曲张出血具有便捷、价廉、疗效肯定和耐受性好等优点,值得推荐为控制食管胃静脉曲张急性活动性出血的首选治疗措施。 Objective To observe and analyse the therapeutic effects and safety of octreotide on esophageal and gastric variceal bleeding (EGVB) with cirrhotic potal hypertension.Methods Ninety EGVB patients with cirrhotic portal hypertension were divided into two groups randomy:Treatment group (48 cases) was treated with octreotide;Control group (42 cases) was treated with pitutrius and nitroglycerin.After discharged from the hospital at two weeks,The indexs such as Total effective rate,Cure rate,Mean time of stop bleeding and adverse effects of drugs in two groups were compared and satistically analysed.Results Total effective rate: treatment group was 93.8%,while control group was 78.6%(P0.05);Cure rate:treatment group was 91.7%,while control group was76.2%(P0.05);Mean time of stop bleeding(h):treatment group was 13.8±6(h),while control group was18.7±5(h)(P0.05) In treatment,no obvious adverse effects were found in both two groups Conclusion The clinic effects of octreotide on EGVB was definite,which were its reliability and safety,low-priced,simple and so on.It was worth recommedding for first choice for treatment measures in clinic.
作者 戚家军 QI Jia-jun (Surgical department,Third People’s Hospital of HunShou County of Hunan Province,Hanshou 415900,China)
出处 《医学信息》 2010年第20期3783-3784,共2页 Journal of Medical Information
关键词 食管胃静脉曲张出血 奥曲肽 垂体后叶素 硝酸甘油 Esophageal and gastric variceal bleeding Octreotide Pituitrius Nitroglycerin
  • 相关文献

参考文献11

  • 1无.肝硬化门静脉高压食管胃静脉曲张出血的防治共识(2008,杭州)[J].中华消化杂志,2008,28(8):551-558. 被引量:154
  • 2吴孟超,吴在德.黄家驷外科学[M].第7版.北京:人民卫生出版社,2008:1340-1341.
  • 3Ziol M,Handrazluca A,Kettaneh A,et al.Non-invasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis c[J].Hepatology,2005,41(1):48-54.
  • 4Corley DA,Cello JP,Adkisson W,et al.Octreotide for acute esophageal variceal bleeding:a meta-andlysis[J].Gastroenterology,2001,120:946-954.
  • 5胡国华,孙益红.门静脉高压症合并上消化道大出血急诊处理[J].中国实用外科杂志,2009,29(5):454-456. 被引量:7
  • 6Franchis RD.Somatostatin,Somatostatin analogues and other vasoactive drugs in the treatment of bleeding esophageal varices[J].Digest Liver Dis,2004,36(1):93-100.
  • 7李宏为,周光文.肝硬化门静脉高压症现状与进展[J].临床外科杂志,2007,15(1):19-21. 被引量:5
  • 8D'Amico G,Pietrosi G,Tarantino I,et al.Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis:a Cochrane meta-analysis[J].Gastroenterology,2003,124:1277-1291.
  • 9Abraldos JG,Angermar B,Bosch J.The management of portal hypertension[J].Clin Liver Dis,2005,9:685-713.
  • 10Vlachogiannakos J,Kougioumtzian A,Triantos C,et al.Clinical trial.The effect of somatostatin vs octreotide in preventing the post-endoscopic increase in hepatic venous pressure gradient in cirrhotic with bleeding varices[J].Aliment Pharmacol Ther,2007,26:1479-1487.

二级参考文献16

共引文献346

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部